DV Trading LLC Buys Shares of 95,253 Enliven Therapeutics, Inc. $ELVN

DV Trading LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 95,253 shares of the company’s stock, valued at approximately $3,734,000. Enliven Therapeutics makes up about 0.1% of DV Trading LLC’s portfolio, making the stock its 16th biggest position.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Avidity Partners Management LP boosted its stake in shares of Enliven Therapeutics by 185.1% in the 1st quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock valued at $15,680,000 after purchasing an additional 259,700 shares in the last quarter. Bank of America Corp DE increased its position in Enliven Therapeutics by 38.1% during the 1st quarter. Bank of America Corp DE now owns 45,162 shares of the company’s stock worth $1,770,000 after purchasing an additional 12,451 shares in the last quarter. Stempoint Capital LP acquired a new position in Enliven Therapeutics during the 1st quarter worth approximately $14,247,000. ADAR1 Capital Management LLC lifted its stake in Enliven Therapeutics by 998.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 329,540 shares of the company’s stock valued at $12,918,000 after purchasing an additional 299,540 shares during the last quarter. Finally, Amundi bought a new position in Enliven Therapeutics in the 1st quarter valued at approximately $272,000. Institutional investors own 95.08% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the transaction, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 32,036 shares of company stock worth $1,430,676. Insiders own 3.00% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $54.81 on Friday. The business’s 50 day simple moving average is $46.75 and its 200 day simple moving average is $38.48. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $55.82. The stock has a market capitalization of $3.34 billion, a PE ratio of -32.82 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, research analysts expect that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ELVN shares. Stifel Nicolaus boosted their target price on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Mizuho increased their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Guggenheim started coverage on Enliven Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective on the stock. HC Wainwright boosted their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.